201. Methylated Alteration of SHP1 Complements Mutation of JAK2 Tyrosine Kinase in Patients with Myeloproliferative Neoplasm
- Author
-
Li-yuan Tang, Shen-meng Gao, Hui Chen, Xiaoqun Zheng, Jian-Bo Wu, Junjun Yang, and Hai-Ying Li
- Subjects
Epigenomics ,STAT3 Transcription Factor ,Antimetabolites, Antineoplastic ,Cancer Research ,Epidemiology ,Blotting, Western ,Molecular Sequence Data ,Decitabine ,Real-Time Polymerase Chain Reaction ,hemic and lymphatic diseases ,Tumor Cells, Cultured ,medicine ,Humans ,RNA, Messenger ,STAT3 ,Myeloproliferative neoplasm ,Myeloproliferative Disorders ,Janus kinase 2 ,Base Sequence ,biology ,Reverse Transcriptase Polymerase Chain Reaction ,Protein Tyrosine Phosphatase, Non-Receptor Type 6 ,Public Health, Environmental and Occupational Health ,food and beverages ,DNA Methylation ,Janus Kinase 2 ,medicine.disease ,Molecular biology ,Leukemia ,Real-time polymerase chain reaction ,Oncology ,Case-Control Studies ,Mutation ,DNA methylation ,Azacitidine ,Cancer research ,STAT protein ,biology.protein ,medicine.drug - Abstract
SHP1 negatively regulates the Janus kinase 2/signal transducer and activator of transcription (JAK2/STAT) signaling pathway, which is constitutively activated in myeloproliferative neoplasms (MPNs) and leukemia. Promoter hypermethylation resulting in epigenetic inactivation of SHP1 has been reported in myelomas, leukemias and other cancers. However, whether SHP1 hypermethylation occurs in MPNs, especially in Chinese patients, has remained unclear. Here, we report that aberrant hypermethylation of SHP1 was observed in several leukemic cell lines and bone marrow mononuclear cells from MPN patients. About 51 of 118 (43.2%) MPN patients including 23 of 50 (46%) polycythaemia vera patients, 20 of 50 (40%) essential thrombocythaemia and 8 of 18 (44.4%) idiopathic myelofibrosis showed hypermethylation by methylation-specific polymerase chain reaction. However, SHP1 methylation was not measured in 20 healthy volunteers. Hypermethylation of SHP1 was found in MPN patients with both positive (34/81, 42%) and negative (17/37, 45.9%) JAK2V617F mutation. The levels of SHP1 mRNA were significantly lower in hypermethylated samples than unmethylated samples, suggesting SHP1 may be epigenetically inactivated in MPN patients. Furthermore, treatment with 5-aza-2'-deoxycytidine (AZA) in K562 cells showing hypermethylation of SHP1 led to progressive demethylation of SHP1, with consequently increased reexpression of SHP1. Meanwhile, phosphorylated JAK2 and STAT3 were progressively reduced. Finally, AZA increased the expression of SHP1 in primary MPN cells with hypermethylation of SHP1. Therefore, our data suggest that epigenetic inactivation of SHP1 contributes to the constitutive activation of JAK2/STAT signaling. Restoration of SHP1 expression by AZA may contribute to clinical treatment for MPN patients.
- Published
- 2015